iCAD Shares On The Rise After FDA Approval For Third Version Of ProFound AI For 3D Mammography

The FDA has approved iCAD Inc’s ICAD ProFound AI Version 3.0 for Digital Breast Tomosynthesis (also known as “3D” mammography used to improve the ability to detect early breast cancers).

• Compared to previous versions of the software, the ProFound AI 3.0 algorithm offers up to a 10% improvement in specificity performance and a 1% improvement in sensitivity.
• The new version also offers up to 40% faster processing.
• Price Action: ICAD shares are trading 16.9% higher at $21.9 in the premarket trading on the last check Tuesday.